Hepatology News
| Jul 29, 2010 – SOURCE: Hepatology | |||
 |
|
Is sexual contact a major mode of hepatitis C virus transmission? | |
| Medical opinion varies considerably regarding the transmission of hepatitis C virus (HCV) through sexual contact. Based on the study design, representativeness of the study population, and the methods used for case ascertainment, we analyzed 80 qualifying | |||
| Jul 29, 2010 – SOURCE: Canadian Journal of Gastroenterology | |||
|
|
Overexpression of cyclooxygenase-2 in noncancerous liver tissue increases the postoperative recurrence of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis | |
| BACKGROUND: Many previous studies have evaluated the histopathological features of tumours as risk factors for postoperative recurrence in hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC). However, there have been few large studies invest | |||
| Jul 28, 2010 – SOURCE: Swiss Medical Weekly | |||
|
|
Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study | |
| BACKGROUND/AIMS: Treatment of chronic HCV infection has become a priority in HIV+ patients, given the faster progression to end-stage liver disease. The primary endpoint of this study was to evaluate and compare antiviral efficacy of Peginterferon alpha 2 | |||
| Jul 28, 2010 – SOURCE: Journal of Surgical Research | |||
|
|
Hepatocellular Carcinoma Survival in Uninsured and Underinsured Patients | |
| BACKGROUND: The incidence of hepatitis C virus (HCV) and hepatocellular carcinoma (HCC) is increasing. The purpose of this study is to establish baseline survival in a medically-underserved population and to evaluate the effect of HCV seropositivity on ou | |||
| Jul 27, 2010 – SOURCE: Journal of Hepatology | |||
|
|
Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir | |
| BACKGROUND&AIMS: Little is known about the optimal management of patients with chronic hepatitis B (CHB) who developed multiple-drug resistance. METHODS: We assessed 91 patients with compensated CHB who developed adefovir-resistant mutations during adefov | |||
| Jul 27, 2010 – SOURCE: Hepatology | |||
|
|
A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B | |
| Serum hepatitis B surface antigen (HBsAg) quantification has been suggested to reflect the concentration of covalently closed circular DNA in the liver. We aimed to investigate the HBsAg levels at different stages of chronic hepatitis B and the changes in | |||
| Jul 27, 2010 – SOURCE: BMC Infectious Diseases | |||
|
|
Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life? | |
| ABSTRACT: BACKGROUND: More than 50% of hepatitis C viruses (HCV)-infected patients do not respond to the classical Interferon (IFN)/Ribavirin (RBV) combination therapy. The aim of this study was to evaluate the efficacy of retreatment with Peg-Interferon | |||
| Jul 27, 2010 – SOURCE: Clinical Infectious Diseases | |||
|
|
Pegylated Interferon Alfa-2a Monotherapy for Hemodialysis Patients with Acute Hepatitis C | |
| Background. Hemodialysis patients are at risk of hepatitis C virus (HCV) infection. However, little is known about the efficacy and safety of pegylated interferon (IFN) therapy for hemodialysis patients with acute hepatitis C. Methods. From 2005 through 2 | |||
| Jul 26, 2010 – SOURCE: European Journal of Gastroenterology and Hepatology | |||
|
|
Early viral and peripheral blood mononuclear cell responses to pegylated interferon and ribavirin treatment: the first 24 h | |
| OBJECTIVES: This study explored gene expression differences in predicting response to pegylated interferon (IFN-PEG) and ribavirin (RBV) in hepatitis C infection. Current treatment for hepatitis C virus (HCV) with IFN-PEG alpha-2a/b and RBV is an expensiv | |||
| Jul 26, 2010 – SOURCE: Advances in Therapy | |||
|
|
Telaprevir: a new hope in the treatment of chronic hepatitis C? | |
| More than 180 million people worldwide have chronic hepatitis C (CHC) virus infection, a major cause of liver cirrhosis and its life-threatening complications including liver failure, portal hypertension, and hepatocellular carcinoma. With the current sta | |||
